FDA examines precision dosing.
- Published in:
- American Journal of Health-System Pharmacy, 2019, v. 76, n. 24, p. 1999, doi. 10.1093/ajhp/zxz269
- By:
- Publication type:
- Article
Works matching DE "FOSAMPRENAVIR (Drug)"
Results: 11
1
2
Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population.
- Published in:
- BMC Infectious Diseases, 2012, v. 12, n. 1, p. 179, doi. 10.1186/1471-2334-12-179
- By:
- Publication type:
- Article
3
Interactions Between Buprenorphine and the Protease Inhibitors Darunavir-Ritonavir and Fosamprenavir-Ritonavir.
- Published in:
- Clinical Infectious Diseases, 2012, v. 54, n. 3, p. 414, doi. 10.1093/cid/cir799
- By:
- Publication type:
- Article
4
High viral load, previous fosamprenavir use and more recent HIV diagnosis correlate with darunavir failure in salvage therapy in Sao Paulo, Brazil.
- Published in:
- Journal of the International AIDS Society, 2012, v. 15, p. 1, doi. 10.7448/IAS.15.6.18269
- By:
- Publication type:
- Article
5
SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients.
- Published in:
- Journal of the International AIDS Society, 2010, v. 13, p. P7, doi. 10.1186/1758-2652-13-S4-P7
- By:
- Publication type:
- Article
6
Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens.
- Published in:
- Journal of the International AIDS Society, 2010, v. 13, p. P136, doi. 10.1186/1758-2652-13-S4-P136
- By:
- Publication type:
- Article
7
Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens.
- Published in:
- 2010
- By:
- Publication type:
- Abstract
8
Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients.
- Published in:
- Journal of Clinical Pharmacology, 2014, v. 54, n. 2, p. 206, doi. 10.1002/jcph.205
- By:
- Publication type:
- Article
9
Clinical Pharmacology Profile of Raltegravir, an HIV-1 Integrase Strand Transfer Inhibitor.
- Published in:
- Journal of Clinical Pharmacology, 2011, v. 51, n. 10, p. 1376, doi. 10.1177/0091270010387428
- By:
- Publication type:
- Article
10
Stability-Indicating HPLC Method for Determination of Fosamprenavir Calcium.
- Published in:
- Journal of Chromatographic Science, 2014, v. 52, n. 8, p. 781, doi. 10.1093/chromsci/bmt110
- By:
- Publication type:
- Article
11
Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study).
- Published in:
- HIV Medicine, 2011, v. 12, n. 7, p. 438, doi. 10.1111/j.1468-1293.2010.00898.x
- By:
- Publication type:
- Article